Brief: CLS Granted Patent In China For Product And Method Of Controlling Treatment With imILT Protocol
23/03/2022 11:03
March 23 (Reuters) - Clinical Laserthermia Systems AB
CLSRb.ST :
* CLS GRANTED PATENT IN CHINA FOR THE PRODUCT AND METHOD OF
CONTROLLING TREATMENT WITH IMILT PROTOCOL
* CHINESE PATENT IS VALID UNTIL 2034 AND PROTECTS CLS
TECHNOLOGY
FOR CONTROLLING HEAT TREATMENT ACCORDING TO CLS IMILT PROTOCOL
Source text for Eikon: ID:nWkrbx60Jz
Further company coverage: CLSRb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Clinical Laserthermia Systems AB
See all newsBrief: Clinical Laserthermia Systems AB Resolves On A Directed Issue
Brief: Clinical Laserthermia Appoints Katarina Lundqvist As Permanent CFO
Brief: CLS Announces Outcome In Rights Issue Of Units
Brief: CLS Agrees On Top-Down Guarantee For Rights Issue
Brief: CLS Conducts Rights Issue Of SEK 39.5 Million